TAO Synergies TAOX
NASDAQ TAOX
$4.14 +0.13 (+3.10%)
As of: Sep 9, 2026 · 1:19 PM EDT

TAO Synergies (TAOX) Liabilities and Shareholders Equity (2019 - 2026)

TAO Synergies' (TAOX) quarterly Liabilities and Shareholders Equity came in at $21.1 million in Q2 2026, up 6.63% on a YoY basis from $19.8 million in Q2 2025, and down 32.03% quarter-over-quarter from $31.0 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $21.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 6.63% year-over-year to $21.1 million; the trailing twelve-month figure through Jun 2026 stood at $96.3 million (up 27.3% YoY), and the FY2025 full-year result was $25.8 million, up 45.68% from the prior year.
  • Liabilities and Shareholders Equity fell to $21.1 million in Q2 2026 per TAOX's latest filing, from $31.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $38.6 million in Q4 2022 and bottomed at $15.3 million in Q1 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $27.3 million across 5 years, with a median of $28.9 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 47.86% in 2025, then surged 102.54% in 2026.
  • Over 5 years, Liabilities and Shareholders Equity stood at $38.6 million in 2022, then dropped by 19.41% to $31.1 million in 2023, then sank by 43.0% to $17.7 million in 2024, then soared by 45.68% to $25.8 million in 2025, then fell by 18.31% to $21.1 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $21.1 million, $31.0 million, and $25.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 10.03 Bn
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn 5.56 Bn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn 32.09 Bn
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn 5.31 Bn
10 TAO Synergies 30.90 Mn 30.90 Mn - 21.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 21.10 Mn
Mar 31, 2026 31.05 Mn
Dec 31, 2025 25.84 Mn
Sep 30, 2025 18.36 Mn
Jun 30, 2025 19.79 Mn
Mar 31, 2025 15.33 Mn
Dec 31, 2024 17.73 Mn
Sep 30, 2024 22.83 Mn
Jun 30, 2024 28.39 Mn
Mar 31, 2024 29.40 Mn
Dec 31, 2023 31.11 Mn
Sep 30, 2023 32.36 Mn
Jun 30, 2023 33.44 Mn
Mar 31, 2023 36.53 Mn
Dec 31, 2022 38.61 Mn
Sep 30, 2022 27.35 Mn
Jun 30, 2022 29.58 Mn
Mar 31, 2022 32.35 Mn
Dec 31, 2021 35.52 Mn
Sep 30, 2021 32.36 Mn